Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...
INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid ...
Interleukin-6 (IL-6) is a pleiotropic cytokine that may play a role in the regulation of various aspects of the immune response, inflammation, hematopoiesis, and bone metabolism. IL-6 acts by binding ...
Long-term treatment with tocilizumab was effective in patients with moderate-to-severe thyroid eye disease (TED) that was resistant to corticosteroids, with 58% of patients achieving clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results